Actinic Keratosis (AK) or solar keratosis are precancerous skin lesions which normally is found on the the epidermis on account of long-term sun exposures. These lesions could potentially become cancerous, hence as a preventive method actinic keratosis treatment is used to prevent skin cancer. The treatment includes topical, surgery, photodynamic surgery. Some of the class of drugs involved in the treatment are nucleoside metabolic inhibitors, NSAIDs, immune response modifiers, photoenhancers.
Market Overview and Trends
As actinic keratosis is the most prevalent class of precancerous skin lesions, hence the preventive strategies adopted are the market drivers. Topical products is most likely to lead the actinic keratosis therapy due to easy availability and deep market penetration. Hospitals end use segment will see high growth ease of accessibility and availability to patients. Nucleoside metabolic inhibitors as a drug class will be growth propeller.
As per geographical breakdown, North America will be the dominant market due to increasing disease prevalence and proactive government initiatives, presence of key manufacturers as well as regulatory entities. Asia Pacific will see the maximum growth due to high prevalence of the disease in southern areas, such as Australia and New Zealand, disposable income and rise in consumer awareness.
Factors Influencing the Market Growth:
• Environmental factors, such as ozone depletion and excessive sun exposure
• Increase in disease prevalence
• Preventive strategies for cancer also propel the market growth
• Awareness campaign among the end users
• Favourable reimbursement policies to expand the affordability
Factors Restraining the Market Growth:
• High cost and risk factors associated with available treatment options
• Safe and effective treatment strategies are needed to optimize clearance of Actinic Keratosis
Market Segmentation 2019-2029:
The Actinic Keratosis Treatment market is segmented by Therapy (Topical, Surgery, Photodynamic Therapy), By Drug Class, By End Use, By Region, And Segment Forecasts
Market Segmentation Covered:
• Global Actinic Keratosis Treatment Therapy Market 2019-2029
– Global Topical Market 2019-2029
– Global Surgery Market 2019-2029
– Global Photodynamic Therapy Market 2019-2029
• Global Actinic Keratosis Treatment by Drug Class Market 2019-2029
– Global Nucleoside Metabolic Inhibitors Market 2019-2029
– Global NSAIDs Market 2019-2029
– Global Immune Response Modifiers Market 2019-2029
– Global Photo enhancers Market 2019-2029
– Global Others Market 2019-2029
• Global Actinic Keratosis Treatment by End Use Market 2019-2029
– Global Hospitals Market 2019-2029
– Global Private Clinics Market 2019-2029
– Global Homecare Market 2019-2029
– Global Others Market 2019-2029
Geographic Breakdown
Focused regional forecasts and analysis explore the future opportunities:
• North America Market, 2019-2029
• Europe Market, 2019-2029
• Asia-Pacific Market, 2019-2029
• LAMEA Market, 2019-2029
Competitive Analysis:
• Research and development is the primary strategy adopted by the key players in the Actinic Keratosis Treatment market.
• These companies have developed various strategies and developments such as product launch, partnerships, mergers & acquisitions, joint venture, and collaborations.
Major Market Players:
Bausch Health Companies Inc.; LEO Pharma A/S; Almirall, S.A.; Biofrontera, Inc.; Nestlé S.A.; Sun Pharmaceutical Industries Ltd.; Novartis International AG; 3M Pharmaceuticals Inc.; Hill Dermaceuticals, Inc.; and Mylan N.V.
Key questions answered by this report:
• What is the current size of the total global Actinic Keratosis Treatment market?
• How much will this market be worth from 2018 to 2029?
• How is the Actinic Keratosis Treatment market evolving?
• What is driving and restraining the Actinic Keratosis Treatment market?
• What are the market shares of each segment of the overall Actinic Keratosis Treatment market currently and how will these change to 2029?
• What are the main submarkets and how much revenue will each Actinic Keratosis Treatment market submarket account for over the next 10 years to 2029 and why?
• How will the market shares for each Actinic Keratosis Treatment market submarket develop from 2018 to 2029?
• Who are the leading players and what are their prospects over the forecast period?
• How will the industry evolve to 2029?
• What are the largest national markets for Actinic Keratosis Treatment market? What is the current status and how will it develop over the next ten years? What are their forecasts for 2019-2029?
• Who are the most prominent companies, and what are their activities and outlooks?
• What are the main trends that will affect the Actinic Keratosis Treatment market between 2018 and 2029?
Visiongain’s study is intended for anyone requiring commercial analyses for the Actinic Keratosis Treatment market. You find data, trends and predictions.
Buy our report today Actinic Keratosis Treatment Market 2019-2029: By Therapy (Topical, Surgery, Photodynamic Therapy), By Drug Class, By End Use, By Region, And Segment Forecasts
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
Do you have any custom requirements we can help you with? Any need for specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com
1 Report Overview
1.1 Global Actinic Keratosis Treatment Market
1.2 Global Actinic Keratosis Treatment Market Overview
1.3 Global Actinic Keratosis Treatment Market Segmentation
1.4 Market Drivers
1.5 Why You Should Read This Report
1.6 How This Report Delivers
1.7 Key Questions Answered by This Analytical Report Include:
1.8 Methodology
1.8.1 Secondary Research
1.9 Frequently Asked Questions (FAQ)
1.10 Associated Visiongain Reports
1.11 About Visiongain
2 Introduction to the Actinic Keratosis Treatment Market
2.1 Actinic Keratosis Treatment Therapy
2.1.1 Topical
2.1.2 Surgery
2.1.3 Photodynamic Therapy
2.2 Actinic Keratosis Treatment by Drug Class
2.2.1 Nucleoside Metabolic Inhibitors
2.2.2 NSAIDs
2.2.3 Immune Response Modifiers
2.2.4 Photo enhancers
2.2.5 Others
2.3 Actinic Keratosis Treatment by End Use
2.3.1 Hospitals
2.3.2 Private Clinics
2.3.3 Homecare
2.3.4 Others
3 Global Actinic Keratosis Treatment Market Analysis
3.1 PEST Analysis of the Actinic Keratosis Treatment Market
3.2 Expert Opinion
3.2.1 Primary Correspondents
3.3 Actinic Keratosis Treatment Market Outlook
3.4 Drivers & Restraints
3.5 Dominant Region/Country
3.6 Actinic Keratosis Treatment Overall Operating Scenario
3.7 Overall Growth Rate, Globally
3.8 SWOT Analysis of the Actinic Keratosis Treatment Market
3.8.1 Strengths
3.8.2 Weaknesses
3.8.3 Opportunities
3.8.4 Threats
4 Actinic Keratosis Treatment: Global Market
4.1 Global Actinic Keratosis Treatment Therapy Market 2019-2029
4.1.1 Global Topical Market 2019-2029
4.1.2 Global Surgery Market 2019-2029
4.1.3 Global Photodynamic Therapy Market 2019-2029
4.2 Global Actinic Keratosis Treatment by Drug Class Market 2019-2029
4.2.1 Global Nucleoside Metabolic Inhibitors Market 2019-2029
4.2.2 Global NSAIDs Market 2019-2029
4.2.3 Global Immune Response Modifiers Market 2019-2029
4.2.4 Global Photo enhancers Market 2019-2029
4.2.5 Global Others Market 2019-2029
4.3 Global Actinic Keratosis Treatment by End Use Market 2019-2029
4.3.1 Global Hospitals Market 2019-2029
4.3.2 Global Private Clinics Market 2019-2029
4.3.3 Global Homecare Market 2019-2029
4.3.4 Global Others Market 2019-2029
5 Leading Regions in Actinic Keratosis Treatment Market 2019-2029
5.1 Regional Overview
5.1.1 North America
5.1.2 Europe
5.1.3 Asia-Pacific
5.1.4 Middle East & Africa
5.1.5 Rest of the World
5.1.6 Leading Countries/ Regions by Actinic Keratosis Treatment Market
5.2 Canada Actinic Keratosis Treatment Market 2019-2029
5.2.1 Canada Actinic Keratosis Treatment Submarket, By Therapy and Drug Class Type Forecast 2019-2029
5.2.2 Canada Actinic Keratosis Treatment Submarket, By End Use Analysis Forecast 2019-2029
5.2.3 Canada Actinic Keratosis Treatment Market Analysis
5.3 U.S. Actinic Keratosis Treatment Market 2019-2029
5.3.1 U.S. Actinic Keratosis Treatment Submarket, By Therapy and Drug Class Type Forecast 2019-2029
5.3.2 U.S. Actinic Keratosis Treatment Submarket, By End Use Analysis Forecast 2019-2029
5.3.3 U.S. Actinic Keratosis Treatment Market Analysis
5.4 Germany Actinic Keratosis Treatment Market 2019-2029
5.4.1 Germany Actinic Keratosis Treatment Submarket, By Therapy and Drug Class Type Forecast 2019-2029
5.4.2 Germany Actinic Keratosis Treatment Submarket, By End Use Analysis Forecast 2019-2029
5.4.3 Germany Actinic Keratosis Treatment Market Analysis
5.5 France Actinic Keratosis Treatment Market 2019-2029
5.5.1 France Actinic Keratosis Treatment Submarket, By Therapy and Drug Class Type Forecast 2019-2029
5.5.2 France Actinic Keratosis Treatment Submarket, By End Use Analysis Forecast 2019-2029
5.5.3 France Actinic Keratosis Treatment Market Analysis
5.6 U.K. Actinic Keratosis Treatment Market 2019-2029
5.6.1 U.K. Actinic Keratosis Treatment Submarket, By Therapy and Drug Class Type Forecast 2019-2029
5.6.2 U.K. Actinic Keratosis Treatment Submarket, By End Use Analysis Forecast 2019-2029
5.6.3 U.K. Actinic Keratosis Treatment Market Analysis
5.7 Italy Actinic Keratosis Treatment Market 2019-2029
5.7.1 Italy Actinic Keratosis Treatment Submarket, By Therapy and Drug Class Type Forecast 2019-2029
5.7.2 Italy Actinic Keratosis Treatment Submarket, By End Use Analysis Forecast 2019-2029
5.7.3 Italy Actinic Keratosis Treatment Market Analysis
5.8 Spain Actinic Keratosis Treatment Market 2019-2029
5.8.1 Spain Actinic Keratosis Treatment Submarket, By Therapy and Drug Class Type Forecast 2019-2029
5.8.2 Spain Actinic Keratosis Treatment Submarket, By End Use Analysis Forecast 2019-2029
5.8.3 Spain Actinic Keratosis Treatment Market Analysis
5.9 China Actinic Keratosis Treatment Market 2019-2029
5.9.1 China Actinic Keratosis Treatment Submarket, By Therapy and Drug Class Type Forecast 2019-2029
5.9.2 China Actinic Keratosis Treatment Submarket, By End Use Analysis Forecast 2019-2029
5.9.3 China Actinic Keratosis Treatment Market Analysis
5.10 Australia Actinic Keratosis Treatment Market 2019-2029
5.10.1 Australia Actinic Keratosis Treatment Submarket, By Therapy and Drug Class Type Forecast 2019-2029
5.10.2 Australia Actinic Keratosis Treatment Submarket, By End Use Analysis Forecast 2019-2029
5.10.3 Australia Actinic Keratosis Treatment Market Analysis
5.11 India Actinic Keratosis Treatment Market 2019-2029
5.11.1 India Actinic Keratosis Treatment Submarket, By Therapy and Drug Class Type Forecast 2019-2029
5.11.2 India Actinic Keratosis Treatment Submarket, By End Use Analysis Forecast 2019-2029
5.11.3 India Actinic Keratosis Treatment Market Analysis
5.12 Indonesia Actinic Keratosis Treatment Market 2019-2029
5.12.1 Indonesia Actinic Keratosis Treatment Submarket, By Therapy and Drug Class Type Forecast 2019-2029
5.12.2 Indonesia Actinic Keratosis Treatment Submarket, By End Use Analysis Forecast 2019-2029
5.13 India Actinic Keratosis Treatment Market 2019-2029
5.13.1 India Actinic Keratosis Treatment Submarket, By Therapy and Drug Class Type Forecast 2019-2029
5.13.2 India Actinic Keratosis Treatment Submarket, By End Use Analysis Forecast 2019-2029
5.13.3 India Actinic Keratosis Treatment Market Analysis
5.14 South Korea Actinic Keratosis Treatment Market 2019-2029
5.14.1 5.13.1 South Korea Actinic Keratosis Treatment Submarket, By Therapy and Drug Class Type Forecast 2019-2029
5.14.2 South Korea Actinic Keratosis Treatment Submarket, By End Use Analysis Forecast 2019-2029
5.14.3 South Korea Actinic Keratosis Treatment Market Analysis
5.15 Rest of Asia Actinic Keratosis Treatment Market 2019-2029
5.15.1 Rest of Asia Actinic Keratosis Treatment Submarket, By Therapy and Drug Class Type Forecast 2019-2029
5.15.2 Rest of Asia Actinic Keratosis Treatment Submarket, By End Use Analysis Forecast 2019-2029
5.15.3 Rest of Asia Actinic Keratosis Treatment Market Analysis
5.16 Middle East Actinic Keratosis Treatment Market 2019-2029
5.16.1 Middle East Actinic Keratosis Treatment Submarket, By Therapy and Drug Class Type Forecast 2019-2029
5.16.2 Middle East Actinic Keratosis Treatment Submarket, By End Use Analysis Forecast 2019-2029
5.16.3 Middle East Actinic Keratosis Treatment Market Analysis
5.17 Africa Actinic Keratosis Treatment Market 2019-2029
5.17.1 Africa Actinic Keratosis Treatment Submarket, By Therapy and Drug Class Type Forecast 2019-2029
5.17.2 Africa Actinic Keratosis Treatment Submarket, By End Use Analysis Forecast 2019-2029
5.17.3 Africa Actinic Keratosis Treatment Market Analysis
5.18 Rest of the World Actinic Keratosis Treatment Market 2019-2029
5.18.1 Rest of the World Actinic Keratosis Treatment Submarket, By Therapy and Drug Class Type Forecast 2019-2029
5.18.2 Rest of the World Actinic Keratosis Treatment Submarket, By End Use Analysis Forecast 2019-2029
5.18.3 Rest of the World Actinic Keratosis Treatment Market Analysis
6 7. Leading Companies in the Actinic Keratosis Treatment Market
6.1 Bausch Health Companies Inc.
6.1.1 Company Overview
6.1.2 Product And Services Overview
6.1.3 Financials Overview
6.1.4 Key Developments
6.1.5 SWOT Analysis
6.2 LEO Pharma A/S
6.2.1 Company Overview
6.2.2 Product And Services Overview
6.2.3 Financial Overview
6.2.4 Key Developments
6.2.5 SWOT Analysis
6.3 Almirall, S.A.
6.3.1 Company Overview
6.3.2 Product And Services Overview
6.3.3 Financial Overview
6.3.4 Key Development
6.3.5 SWOT Analysis
6.4 Biofrontera, Inc.
6.4.1 Company Overview
6.4.2 Product And Services Overview
6.4.3 Financial Overview
6.4.4 Key Development
6.4.5 SWOT Analysis
6.5 Nestlé S.A.
6.5.1 Company Overview
6.5.2 Product And Services Overview
6.5.3 Financial Overview
6.5.4 Key Developments
6.5.5 SWOT Analysis
6.6 Sun Pharmaceutical Industries Ltd.
6.6.1 Company Overview
6.6.2 Product And Services Overview
6.6.3 Financial Overview
6.6.4 Key Developments
6.6.5 SWOT Analysis
6.7 Novartis International AG
6.7.1 Overview
6.7.2 Product And Services Overview
6.7.3 Financial Overview
6.7.4 Key Developments
6.7.5 SWOT Analysis
6.8 3M Pharmaceuticals Inc.
6.8.1 Overview
6.8.2 Product And Services Overview
6.8.3 Financials
6.8.4 Key Developments
6.8.5 SWOT Analysis
6.9 Hill Dermaceuticals, Inc.
6.9.1 Overview
6.9.2 Product And Services Overview
6.9.3 Financials
6.9.4 Key Developments
6.9.5 SWOT Analysis
6.10 Mylan N.V.
6.10.1 Overview
6.10.2 Product And Services Overview
6.10.3 Financials
6.10.4 Key Developments
6.10.5 SWOT Analysis
7 Conclusions and Recommendations
7.1 Global Actinic Keratosis Treatment Market Outlook
7.2 Recommendations
8 Glossary
8.1 Associated Visiongain Reports
8.2 Visiongain Report Sales Order Form
8.3 Appendix A
8.4 About Visiongain
8.5 Appendix B
8.6 Visiongain Report Evaluation Form
List of Tables
Table 3.1 PEST Analysis of the Actinic Keratosis Treatment Market
Table 3.8 SWOT Analysis of the Actinic Keratosis Treatment Market
Table 4.1 Global Actinic Keratosis Treatment Therapy Market 2019-2029
Table 4.1.1 Global Topical Market 2019-2029
Table 4.1.2 Global Surgery Market 2019-2029
Table 4.1.3 Global Photodynamic Therapy Market 2019-2029
Table 4.2 Global Actinic Keratosis Treatment by Drug Class Market 2019-2029
Table 4.2.1 Global Nucleoside Metabolic Inhibitors Market 2019-2029
Table 4.2.2 Global NSAIDs Market 2019-2029
Table 4.2.3 Global Immune Response Modifiers Market 2019-2029
Table 4.2.4 Global Photo enhancers Market 2019-2029
Table 4.2.5 Global Others Market 2019-2029
Table 4.3 Global Actinic Keratosis Treatment by End Use Market 2019-2029
Table 4.3.1 Global Hospitals Market 2019-2029
Table 4.3.2 Global Private Clinics Market 2019-2029
Table 4.3.3 Global Homecare Market 2019-2029
Table 4.3.4 Global Others Market 2019-2029
Table 5.2 Canada Actinic Keratosis Treatment Market 2019-2029
Table 5.2.1 Canada Actinic Keratosis Treatment Submarket, By Therapy and Drug Class Type Forecast 2019-2029
Table 5.2.2 Canada Actinic Keratosis Treatment Submarket, By End Use Analysis Forecast 2019-2029
Table 5.2.3 Canada Actinic Keratosis Treatment Market Analysis
Table 5.3 U.S. Actinic Keratosis Treatment Market 2019-2029
Table 5.3.1 U.S. Actinic Keratosis Treatment Submarket, By Therapy and Drug Class Type Forecast 2019-2029
Table 5.3.2 U.S. Actinic Keratosis Treatment Submarket, By End Use Analysis Forecast 2019-2029
Table 5.3.3 U.S. Actinic Keratosis Treatment Market Analysis
Table 5.4 Germany Actinic Keratosis Treatment Market 2019-2029
Table 5.4.1 Germany Actinic Keratosis Treatment Submarket, By Therapy and Drug Class Type Forecast 2019-2029
Table 5.4.2 Germany Actinic Keratosis Treatment Submarket, By End Use Analysis Forecast 2019-2029
Table 5.4.3 Germany Actinic Keratosis Treatment Market Analysis
Table 5.5 France Actinic Keratosis Treatment Market 2019-2029
Table 5.5.1 France Actinic Keratosis Treatment Submarket, By Therapy and Drug Class Type Forecast 2019-2029
Table 5.5.2 France Actinic Keratosis Treatment Submarket, By End Use Analysis Forecast 2019-2029
Table 5.5.3 France Actinic Keratosis Treatment Market Analysis
Table 5.6 U.K. Actinic Keratosis Treatment Market 2019-2029
Table 5.6.1 U.K. Actinic Keratosis Treatment Submarket, By Therapy and Drug Class Type Forecast 2019-2029
Table 5.6.2 U.K. Actinic Keratosis Treatment Submarket, By End Use Analysis Forecast 2019-2029
Table 5.6.3 U.K. Actinic Keratosis Treatment Market Analysis
Table 5.7 Italy Actinic Keratosis Treatment Market 2019-2029
Table 5.7.1 Italy Actinic Keratosis Treatment Submarket, By Therapy and Drug Class Type Forecast 2019-2029
Table 5.7.2 Italy Actinic Keratosis Treatment Submarket, By End Use Analysis Forecast 2019-2029
Table 5.7.3 Italy Actinic Keratosis Treatment Market Analysis
Table 5.8 Spain Actinic Keratosis Treatment Market 2019-2029
Table 5.8.1 Spain Actinic Keratosis Treatment Submarket, By Therapy and Drug Class Type Forecast 2019-2029
Table 5.8.2 Spain Actinic Keratosis Treatment Submarket, By End Use Analysis Forecast 2019-2029
Table 5.8.3 Spain Actinic Keratosis Treatment Market Analysis
Table 5.9 China Actinic Keratosis Treatment Market 2019-2029
Table 5.9.1 China Actinic Keratosis Treatment Submarket, By Therapy and Drug Class Type Forecast 2019-2029
Table 5.9.2 China Actinic Keratosis Treatment Submarket, By End Use Analysis Forecast 2019-2029
Table 5.9.3 China Actinic Keratosis Treatment Market Analysis
Table 5.10 Australia Actinic Keratosis Treatment Market 2019-2029
Table 5.10.1 Australia Actinic Keratosis Treatment Submarket, By Therapy and Drug Class Type Forecast 2019-2029
Table 5.10.2 Australia Actinic Keratosis Treatment Submarket, By End Use Analysis Forecast 2019-2029
Table 5.10.3 Australia Actinic Keratosis Treatment Market Analysis
Table 5.11 India Actinic Keratosis Treatment Market 2019-2029
Table 5.11.1 India Actinic Keratosis Treatment Submarket, By Therapy and Drug Class Type Forecast 2019-2029
Table 5.11.2 India Actinic Keratosis Treatment Submarket, By End Use Analysis Forecast 2019-2029
Table 5.11.3 India Actinic Keratosis Treatment Market Analysis
Table 5.12 Indonesia Actinic Keratosis Treatment Market 2019-2029
Table 5.12.1 Indonesia Actinic Keratosis Treatment Submarket, By Therapy and Drug Class Type Forecast 2019-2029
Table 5.12.2 Indonesia Actinic Keratosis Treatment Submarket, By End Use Analysis Forecast 2019-2029
Table 5.13 India Actinic Keratosis Treatment Market 2019-2029
Table 5.13.1 India Actinic Keratosis Treatment Submarket, By Therapy and Drug Class Type Forecast 2019-2029
Table 5.13.2 India Actinic Keratosis Treatment Submarket, By End Use Analysis Forecast 2019-2029
Table 5.13.3 India Actinic Keratosis Treatment Market Analysis
Table 5.14 South Korea Actinic Keratosis Treatment Market 2019-2029
Table 5.14.1 5.13.1 South Korea Actinic Keratosis Treatment Submarket, By Therapy and Drug Class Type Forecast 2019-2029
Table 5.14.2 South Korea Actinic Keratosis Treatment Submarket, By End Use Analysis Forecast 2019-2029
Table 5.14.3 South Korea Actinic Keratosis Treatment Market Analysis
Table 5.15 Rest of Asia Actinic Keratosis Treatment Market 2019-2029
Table 5.15.1 Rest of Asia Actinic Keratosis Treatment Submarket, By Therapy and Drug Class Type Forecast 2019-2029
Table 5.15.2 Rest of Asia Actinic Keratosis Treatment Submarket, By End Use Analysis Forecast 2019-2029
Table 5.15.3 Rest of Asia Actinic Keratosis Treatment Market Analysis
Table 5.16 Middle East Actinic Keratosis Treatment Market 2019-2029
Table 5.16.1 Middle East Actinic Keratosis Treatment Submarket, By Therapy and Drug Class Type Forecast 2019-2029
Table 5.16.2 Middle East Actinic Keratosis Treatment Submarket, By End Use Analysis Forecast 2019-2029
Table 5.16.3 Middle East Actinic Keratosis Treatment Market Analysis
Table 5.17 Africa Actinic Keratosis Treatment Market 2019-2029
Table 5.17.1 Africa Actinic Keratosis Treatment Submarket, By Therapy and Drug Class Type Forecast 2019-2029
Table 5.17.2 Africa Actinic Keratosis Treatment Submarket, By End Use Analysis Forecast 2019-2029
Table 5.17.3 Africa Actinic Keratosis Treatment Market Analysis
Table 5.18 Rest of the World Actinic Keratosis Treatment Market 2019-2029
Table 5.18.1 Rest of the World Actinic Keratosis Treatment Submarket, By Therapy and Drug Class Type Forecast 2019-2029
Table 5.18.2 Rest of the World Actinic Keratosis Treatment Submarket, By End Use Analysis Forecast 2019-2029
Table 5.18.3 Rest of the World Actinic Keratosis Treatment Market Analysis
Table 6.1.3 Bausch Health Companies Inc. Profile 2019 (Market Entry, Public/Private, Headquarter, Total Company Revenue $bn, Change in Revenue, Geography, Key Market, Listed on, Products/Services, No. of Employees)
Table 6.1.5 Bausch Health Companies Inc. Total Company Sales 2014-2019 (US$ bn, AGR %)
Table 6.2.3 LEO Pharma A/S Profile 2019 (Market Entry, Public/Private, Headquarter, Total Company Revenue $bn, Change in Revenue, Geography, Key Market, Listed on, Products/Services, No. of Employees)
Table 6.2.5 LEO Pharma A/S Total Company Sales 2014-2019 (US$ bn, AGR %)
Table 6.3.3 Almirall, S.A. Profile 2019 (Market Entry, Public/Private, Headquarter, Total Company Revenue $bn, Change in Revenue, Geography, Key Market, Listed on, Products/Services, No. of Employees)
Table 6.3.5 Almirall, S.A. Total Company Sales 2014-2019 (US$ bn, AGR %)
Table 6.4.3 Biofrontera, Inc. Profile 2019 (Market Entry, Public/Private, Headquarter, Total Company Revenue $bn, Change in Revenue, Geography, Key Market, Listed on, Products/Services, No. of Employees)
Table 6.4.5 Biofrontera, Inc. Total Company Sales 2014-2019 (US$ bn, AGR %)
Table 6.5.3 Nestlé S.A. Profile 2019 (Market Entry, Public/Private, Headquarter, Total Company Revenue $bn, Change in Revenue, Geography, Key Market, Listed on, Products/Services, No. of Employees)
Table 6.5.5 Nestlé S.A. Total Company Sales 2014-2019 (US$ bn, AGR %)
Table 6.6.3 Sun Pharmaceutical Industries Ltd. Profile 2019 (Market Entry, Public/Private, Headquarter, Total Company Revenue $bn, Change in Revenue, Geography, Key Market, Listed on, Products/Services, No. of Employees)
Table 6.6.5 Sun Pharmaceutical Industries Ltd. Total Company Sales 2014-2019 (US$ bn, AGR %)
Table 6.7.3 Novartis International AG Profile 2019 (Market Entry, Public/Private, Headquarter, Total Company Revenue $bn, Change in Revenue, Geography, Key Market, Listed on, Products/Services, No. of Employees)
Table 6.7.5 Novartis International AG Total Company Sales 2014-2019 (US$ bn, AGR %)
Table 6.8.3 3M Pharmaceuticals Inc. Profile 2019 (Market Entry, Public/Private, Headquarter, Total Company Revenue $bn, Change in Revenue, Geography, Key Market, Listed on, Products/Services, No. of Employees)
Table 6.8.5 3M Pharmaceuticals Inc. Total Company Sales 2014-2019 (US$ bn, AGR %)
Table 6.9.3 Hill Dermaceuticals, Inc. Profile 2019 (Market Entry, Public/Private, Headquarter, Total Company Revenue $bn, Change in Revenue, Geography, Key Market, Listed on, Products/Services, No. of Employees)
Table 6.9.5 Hill Dermaceuticals, Inc. Total Company Sales 2014-2019 (US$ bn, AGR %)
Table 6.10.3 Mylan N.V. Profile 2019 (Market Entry, Public/Private, Headquarter, Total Company Revenue $bn, Change in Revenue, Geography, Key Market, Listed on, Products/Services, No. of Employees)
Table 6.10.5 Mylan N.V. Total Company Sales 2014-2019 (US$ bn, AGR %)
List of Figures
Figure 1.1 Global Actinic Keratosis Treatment Market Segmentation
Figure 4.1 Global Actinic Keratosis Treatment Therapy Market 2019-2029
Figure 4.1.1 Global Topical Market 2019-2029
Figure 4.1.2 Global Surgery Market 2019-2029
Figure 4.1.3 Global Photodynamic Therapy Market 2019-2029
Figure 4.2 Global Actinic Keratosis Treatment by Drug Class Market 2019-2029
Figure 4.2.1 Global Nucleoside Metabolic Inhibitors Market 2019-2029
Figure 4.2.2 Global NSAIDs Market 2019-2029
Figure 4.2.3 Global Immune Response Modifiers Market 2019-2029
Figure 4.2.4 Global Photo enhancers Market 2019-2029
Figure 4.2.5 Global Others Market 2019-2029
Figure 4.3 Global Actinic Keratosis Treatment by End Use Market 2019-2029
Figure 4.3.1 Global Hospitals Market 2019-2029
Figure 4.3.2 Global Private Clinics Market 2019-2029
Figure 4.3.3 Global Homecare Market 2019-2029
Figure 4.3.4 Global Others Market 2019-2029
Figure 5.2 Canada Actinic Keratosis Treatment Market 2019-2029
Figure 5.2.1 Canada Actinic Keratosis Treatment Submarket, By Therapy and Drug Class Type Forecast 2019-2029
Figure 5.2.2 Canada Actinic Keratosis Treatment Submarket, By End Use Analysis Forecast 2019-2029
Figure 5.2.3 Canada Actinic Keratosis Treatment Market Analysis
Figure 5.3 U.S. Actinic Keratosis Treatment Market 2019-2029
Figure 5.3.1 U.S. Actinic Keratosis Treatment Submarket, By Therapy and Drug Class Type Forecast 2019-2029
Figure 5.3.2 U.S. Actinic Keratosis Treatment Submarket, By End Use Analysis Forecast 2019-2029
Figure 5.3.3 U.S. Actinic Keratosis Treatment Market Analysis
Figure 5.4 Germany Actinic Keratosis Treatment Market 2019-2029
Figure 5.4.1 Germany Actinic Keratosis Treatment Submarket, By Therapy and Drug Class Type Forecast 2019-2029
Figure 5.4.2 Germany Actinic Keratosis Treatment Submarket, By End Use Analysis Forecast 2019-2029
Figure 5.4.3 Germany Actinic Keratosis Treatment Market Analysis
Figure 5.5 France Actinic Keratosis Treatment Market 2019-2029
Figure 5.5.1 France Actinic Keratosis Treatment Submarket, By Therapy and Drug Class Type Forecast 2019-2029
Figure 5.5.2 France Actinic Keratosis Treatment Submarket, By End Use Analysis Forecast 2019-2029
Figure 5.5.3 France Actinic Keratosis Treatment Market Analysis
Figure 5.6 U.K. Actinic Keratosis Treatment Market 2019-2029
Figure 5.6.1 U.K. Actinic Keratosis Treatment Submarket, By Therapy and Drug Class Type Forecast 2019-2029
Figure 5.6.2 U.K. Actinic Keratosis Treatment Submarket, By End Use Analysis Forecast 2019-2029
Figure 5.6.3 U.K. Actinic Keratosis Treatment Market Analysis
Figure 5.7 Italy Actinic Keratosis Treatment Market 2019-2029
Figure 5.7.1 Italy Actinic Keratosis Treatment Submarket, By Therapy and Drug Class Type Forecast 2019-2029
Figure 5.7.2 Italy Actinic Keratosis Treatment Submarket, By End Use Analysis Forecast 2019-2029
Figure 5.7.3 Italy Actinic Keratosis Treatment Market Analysis
Figure 5.8 Spain Actinic Keratosis Treatment Market 2019-2029
Figure 5.8.1 Spain Actinic Keratosis Treatment Submarket, By Therapy and Drug Class Type Forecast 2019-2029
Figure 5.8.2 Spain Actinic Keratosis Treatment Submarket, By End Use Analysis Forecast 2019-2029
Figure 5.8.3 Spain Actinic Keratosis Treatment Market Analysis
Figure 5.9 China Actinic Keratosis Treatment Market 2019-2029
Figure 5.9.1 China Actinic Keratosis Treatment Submarket, By Therapy and Drug Class Type Forecast 2019-2029
Figure 5.9.2 China Actinic Keratosis Treatment Submarket, By End Use Analysis Forecast 2019-2029
Figure 5.9.3 China Actinic Keratosis Treatment Market Analysis
Figure 5.10 Australia Actinic Keratosis Treatment Market 2019-2029
Figure 5.10.1 Australia Actinic Keratosis Treatment Submarket, By Therapy and Drug Class Type Forecast 2019-2029
Figure 5.10.2 Australia Actinic Keratosis Treatment Submarket, By End Use Analysis Forecast 2019-2029
Figure 5.10.3 Australia Actinic Keratosis Treatment Market Analysis
Figure 5.11 India Actinic Keratosis Treatment Market 2019-2029
Figure 5.11.1 India Actinic Keratosis Treatment Submarket, By Therapy and Drug Class Type Forecast 2019-2029
Figure 5.11.2 India Actinic Keratosis Treatment Submarket, By End Use Analysis Forecast 2019-2029
Figure 5.11.3 India Actinic Keratosis Treatment Market Analysis
Figure 5.12 Indonesia Actinic Keratosis Treatment Market 2019-2029
Figure 5.12.1 Indonesia Actinic Keratosis Treatment Submarket, By Therapy and Drug Class Type Forecast 2019-2029
Figure 5.12.2 Indonesia Actinic Keratosis Treatment Submarket, By End Use Analysis Forecast 2019-2029
Figure 5.13 India Actinic Keratosis Treatment Market 2019-2029
Figure 5.13.1 India Actinic Keratosis Treatment Submarket, By Therapy and Drug Class Type Forecast 2019-2029
Figure 5.13.2 India Actinic Keratosis Treatment Submarket, By End Use Analysis Forecast 2019-2029
Figure 5.13.3 India Actinic Keratosis Treatment Market Analysis
Figure 5.14 South Korea Actinic Keratosis Treatment Market 2019-2029
Figure 5.14.1 5.13.1 South Korea Actinic Keratosis Treatment Submarket, By Therapy and Drug Class Type Forecast 2019-2029
Figure 5.14.2 South Korea Actinic Keratosis Treatment Submarket, By End Use Analysis Forecast 2019-2029
Figure 5.14.3 South Korea Actinic Keratosis Treatment Market Analysis
Figure 5.15 Rest of Asia Actinic Keratosis Treatment Market 2019-2029
Figure 5.15.1 Rest of Asia Actinic Keratosis Treatment Submarket, By Therapy and Drug Class Type Forecast 2019-2029
Figure 5.15.2 Rest of Asia Actinic Keratosis Treatment Submarket, By End Use Analysis Forecast 2019-2029
Figure 5.15.3 Rest of Asia Actinic Keratosis Treatment Market Analysis
Figure 5.16 Middle East Actinic Keratosis Treatment Market 2019-2029
Figure 5.16.1 Middle East Actinic Keratosis Treatment Submarket, By Therapy and Drug Class Type Forecast 2019-2029
Figure 5.16.2 Middle East Actinic Keratosis Treatment Submarket, By End Use Analysis Forecast 2019-2029
Figure 5.16.3 Middle East Actinic Keratosis Treatment Market Analysis
Figure 5.17 Africa Actinic Keratosis Treatment Market 2019-2029
Figure 5.17.1 Africa Actinic Keratosis Treatment Submarket, By Therapy and Drug Class Type Forecast 2019-2029
Figure 5.17.2 Africa Actinic Keratosis Treatment Submarket, By End Use Analysis Forecast 2019-2029
Figure 5.17.3 Africa Actinic Keratosis Treatment Market Analysis
Figure 5.18 Rest of the World Actinic Keratosis Treatment Market 2019-2029
Figure 5.18.1 Rest of the World Actinic Keratosis Treatment Submarket, By Therapy and Drug Class Type Forecast 2019-2029
Figure 5.18.2 Rest of the World Actinic Keratosis Treatment Submarket, By End Use Analysis Forecast 2019-2029
Figure 5.18.3 Rest of the World Actinic Keratosis Treatment Market Analysis
Figure 6.1.3 Bausch Health Companies Inc. Profile 2019 (Market Entry, Public/Private, Headquarter, Total Company Revenue $bn, Change in Revenue, Geography, Key Market, Listed on, Products/Services, No. of Employees)
Figure 6.1.5 Bausch Health Companies Inc. Total Company Sales 2014-2019 (US$ bn, AGR %)
Figure 6.2.3 LEO Pharma A/S Profile 2019 (Market Entry, Public/Private, Headquarter, Total Company Revenue $bn, Change in Revenue, Geography, Key Market, Listed on, Products/Services, No. of Employees)
Figure 6.2.5 LEO Pharma A/S Total Company Sales 2014-2019 (US$ bn, AGR %)
Figure 6.3.3 Almirall, S.A. Profile 2019 (Market Entry, Public/Private, Headquarter, Total Company Revenue $bn, Change in Revenue, Geography, Key Market, Listed on, Products/Services, No. of Employees)
Figure 6.3.5 Almirall, S.A. Total Company Sales 2014-2019 (US$ bn, AGR %)
Figure 6.4.3 Biofrontera, Inc. Profile 2019 (Market Entry, Public/Private, Headquarter, Total Company Revenue $bn, Change in Revenue, Geography, Key Market, Listed on, Products/Services, No. of Employees)
Figure 6.4.5 Biofrontera, Inc. Total Company Sales 2014-2019 (US$ bn, AGR %)
Figure 6.5.3 Nestlé S.A. Profile 2019 (Market Entry, Public/Private, Headquarter, Total Company Revenue $bn, Change in Revenue, Geography, Key Market, Listed on, Products/Services, No. of Employees)
Figure 6.5.5 Nestlé S.A. Total Company Sales 2014-2019 (US$ bn, AGR %)
Figure 6.6.3 Sun Pharmaceutical Industries Ltd. Profile 2019 (Market Entry, Public/Private, Headquarter, Total Company Revenue $bn, Change in Revenue, Geography, Key Market, Listed on, Products/Services, No. of Employees)
Figure 6.6.5 Sun Pharmaceutical Industries Ltd. Total Company Sales 2014-2019 (US$ bn, AGR %)
Figure 6.7.3 Novartis International AG Profile 2019 (Market Entry, Public/Private, Headquarter, Total Company Revenue $bn, Change in Revenue, Geography, Key Market, Listed on, Products/Services, No. of Employees)
Figure 6.7.5 Novartis International AG Total Company Sales 2014-2019 (US$ bn, AGR %)
Figure 6.8.3 3M Pharmaceuticals Inc. Profile 2019 (Market Entry, Public/Private, Headquarter, Total Company Revenue $bn, Change in Revenue, Geography, Key Market, Listed on, Products/Services, No. of Employees)
Figure 6.8.5 3M Pharmaceuticals Inc. Total Company Sales 2014-2019 (US$ bn, AGR %)
Figure 6.9.3 Hill Dermaceuticals, Inc. Profile 2019 (Market Entry, Public/Private, Headquarter, Total Company Revenue $bn, Change in Revenue, Geography, Key Market, Listed on, Products/Services, No. of Employees)
Figure 6.9.5 Hill Dermaceuticals, Inc. Total Company Sales 2014-2019 (US$ bn, AGR %)
Figure 6.10.3 Mylan N.V. Profile 2019 (Market Entry, Public/Private, Headquarter, Total Company Revenue $bn, Change in Revenue, Geography, Key Market, Listed on, Products/Services, No. of Employees)
Figure 6.10.5 Mylan N.V. Total Company Sales 2014-2019 (US$ bn, AGR %)
3M Pharmaceuticals Inc.
Almirall, S.A.
Bausch Health Companies Inc.
Biofrontera, Inc.; Nestlé S.A.
Hill Dermaceuticals, Inc.
LEO Pharma A/S
Mylan N.V.
Novartis International AG
Sun Pharmaceutical Industries Ltd.
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
